A novel acetylcholinesterase inhibitor and calcium channel blocker SCR-1693 improves Aβ25–35-impaired mouse cognitive function
- 580 Downloads
The mechanism involved in AD is complex, which has prompted to develop compounds that could simultaneously interact with several potential targets. Here, we report a new synthesized compound SCR-1693 which is designed to target both AChE and calcium channels that are potential for AD therapy.
We investigated the effects of SCR-1693 on AChE and calcium channels, the effects of neuroprotection and anti-amnesia in icv-Aβ25–35-injected mice, and the potential mechanisms.
AChE activity assay, intracellular Ca2+ content and calcium currents measurement, and Aβ25–35-induced cellular death determine were performed for validation of designed targets and neuroprotection of SCR-1693. Mice were orally administrated with SCR-1693 once daily after an Aβ25–35 injection. The Morris water maze and Y-maze test, and hippocampal protein detection were conducted on days 5–10, day 11, and day 8. The pyramidal neuron number, hippocampal AChE activity, and synaptic transmission were measured on day 12.
SCR-1693 acted as a selective, reversible, and noncompetitive inhibitor of AChE, and a nonselective voltage-gated calcium channel blocker. SCR-1693 also inhibited the increase of AChE activity in the mouse hippocampus. SCR-1693 was more effective than donepezil and memantine in preventing Aβ25–35-induced long-term and short-term memory impairment, maintaining the basal transmission of Schaffer collateral-CA1 synapses, and sustaining LTP in mouse hippocampus. SCR-1693 attenuated Aβ25–35-induced death of SH-SY5Y cell and the loss of hippocampal pyramidal neurons, and regulated Aβ25–35-induced signal cascade in neurons.
All these findings indicated that SCR-1693, as a double-target-direction agent, is a considerable candidate for AD therapy.
KeywordsSCR-1693 AChE inhibitor VGCCs blocker Neuroprotection β-Amyloid Learning and memory
Amyloid β25–35 peptide
Calcium channel blocker
Field excitatory postsynaptic potential
Voltage-gated calcium channel
This work was supported by Jiangsu Simovay Pharmaceutical Co., Ltd (Nanjing, China) and the grant from the National Natural Science Foundation of China (No. 81471557).
Compliance with ethical standards
Conflict of interest
The authors declare no conflicts of interest.
- Anand R, Gill KD, Mahdi AA (2014) Therapeutics of Alzheimer’s disease: past, present and future. Neuropharmacology 76 Pt A: 27–50. doi: 10.1016/j.neuropharm.2013.07.004
- Dominguez Mancera B, Monjaraz Guzman E, Flores-Hernandez JL, Barrientos Morales M, Martinez Hernandez JM, Hernandez Beltran A, Cervantes Acosta P (2013) Potassium current is not affected by long-term exposure to ghrelin or GHRP-6 in somatotropes GC cells. J Biophys 2013:913792. doi: 10.1155/2013/913792 PubMedCentralCrossRefPubMedGoogle Scholar
- Figueiredo CP, Clarke JR, Ledo JH, Ribeiro FC, Costa CV, Melo HM, Mota-Sales AP, Saraiva LM, Klein WL, Sebollela A, De Felice FG, Ferreira ST (2013) Memantine rescues transient cognitive impairment caused by high-molecular-weight abeta oligomers but not the persistent impairment induced by low-molecular-weight oligomers. J Neurosci Off J Soc Neurosci 33:9626–34. doi: 10.1523/JNEUROSCI.0482-13.2013 CrossRefGoogle Scholar
- Klementiev B, Novikova T, Novitskaya V, Walmod PS, Dmytriyeva O, Pakkenberg B, Berezin V, Bock E (2007) A neural cell adhesion molecule-derived peptide reduces neuropathological signs and cognitive impairment induced by Abeta25-35. Neuroscience 145:209–24. doi: 10.1016/j.neuroscience.2006.11.060 CrossRefPubMedGoogle Scholar
- Kume T, Sugimoto M, Takada Y, Yamaguchi T, Yonezawa A, Katsuki H, Sugimoto H, Akaike A (2005) Up-regulation of nicotinic acetylcholine receptors by central-type acetylcholinesterase inhibitors in rat cortical neurons. Eur J Pharmacol 527:77–85. doi: 10.1016/j.ejphar.2005.10.028 CrossRefPubMedGoogle Scholar
- Kwon SH, Lee HK, Kim JA, Hong SI, Kim SY, Jo TH, Park YI, Lee CK, Kim YB, Lee SY, Jang CG (2011) Neuroprotective effects of Eucommia ulmoides Oliv. Bark on amyloid beta(25–35)-induced learning and memory impairments in mice. Neurosci Lett 487:123–7. doi: 10.1016/j.neulet.2010.10.042 CrossRefPubMedGoogle Scholar
- Lahmy V, Meunier J, Malmstrom S, Naert G, Givalois L, Kim SH, Villard V, Vamvakides A, Maurice T (2013) Blockade of Tau hyperphosphorylation and Abeta(1)(−)(4)(2) generation by the aminotetrahydrofuran derivative ANAVEX2-73, a mixed muscarinic and sigma(1) receptor agonist, in a nontransgenic mouse model of Alzheimer’s disease. Neuropsychopharmacology 38:1706–23. doi: 10.1038/npp.2013.70 PubMedCentralCrossRefPubMedGoogle Scholar
- Marco-Contelles J, Ríos Cdl RRL, Samadi A, Bartolini M, Andrisano V, Huertas O, Barril X, Luque F, Rodríguez-Franco M, López B, López M, García A, Carreiras M, Villarroya M (2009) Tacripyrines, the first tacrine-dihydropyridine hybrids, as multitarget-directed ligands for the treatment of Alzheimer’s disease. J Med Chem 52:2724–32CrossRefPubMedGoogle Scholar
- Meunier J, Ieni J, Maurice T (2006) The anti-amnesic and neuroprotective effects of donepezil against amyloid beta 25-35 peptide-induced toxicity in mice involve an interaction with the sigma1 receptor. Br J Pharmacol 149:998–1012. doi: 10.1038/sj.bjp.0706927 PubMedCentralCrossRefPubMedGoogle Scholar
- Paris D, Bachmeier C, Patel N, Quadros A, Volmar CH, Laporte V, Ganey J, Beaulieu-Abdelahad D, Ait-Ghezala G, Crawford F, Mullan MJ (2011) Selective antihypertensive dihydropyridines lower Abeta accumulation by targeting both the production and the clearance of Abeta across the blood-brain barrier. Mol Med 17:149–62. doi: 10.2119/molmed.2010.00180 PubMedCentralCrossRefPubMedGoogle Scholar
- Racaniello M, Cardinale A, Mollinari C, D’Antuono M, De Chiara G, Tancredi V, Merlo D (2010) Phosphorylation changes of CaMKII, ERK1/2, PKB/Akt kinases and CREB activation during early long-term potentiation at Schaffer collateral-CA1 mouse hippocampal synapses. Neurochem Res 35:239–46. doi: 10.1007/s11064-009-0047-0 CrossRefPubMedGoogle Scholar
- Reese LC, Laezza F, Woltjer R, Taglialatela G (2011) Dysregulated phosphorylation of Ca(2+)/calmodulin-dependent protein kinase II-alpha in the hippocampus of subjects with mild cognitive impairment and Alzheimer’s disease. J Neurochem 119:791–804. doi: 10.1111/j.1471-4159.2011.07447.x PubMedCentralCrossRefPubMedGoogle Scholar
- Stepanichev MY, Moiseeva YV, Lazareva NA, Onufriev MV, Gulyaeva NV (2003) Single intracerebroventricular administration of amyloid-beta (25–35) peptide induces impairment in short-term rather than long-term memory in rats. Brain Res Bull 61:197–205. doi: 10.1016/s0361-9230(03)00118-7 CrossRefPubMedGoogle Scholar
- Wang C, Chen T, Li G, Zhou L, Sha S, Chen L (2015) Simvastatin prevents beta-amyloid-impaired neurogenesis in hippocampal dentate gyrus through alpha7nAChR-dependent cascading PI3K-Akt and increasing BDNF via reduction of farnesyl pyrophosphate. Neuropharmacology 97:122–132. doi: 10.1016/j.neuropharm.2015.05.020 CrossRefPubMedGoogle Scholar
- Zussy C, Brureau A, Delair B, Marchal S, Keller E, Ixart G, Naert G, Meunier J, Chevallier N, Maurice T, Givalois L (2011) Time-course and regional analyses of the physiopathological changes induced after cerebral injection of an amyloid beta fragment in rats. Am J Pathol 179:315–34. doi: 10.1016/j.ajpath.2011.03.021 PubMedCentralCrossRefPubMedGoogle Scholar